WGS
GeneDx Holdings Corp.141.72
-8.89-5.9%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A affirms guidance, flags NICU traction.
Q&A largely reaffirms prepared guidance but adds granular modeling details, emphasizing conservative assumptions that bake in Q1 volume/revenue growth at 33% amid seasonal deductibles and weather, with foundational markets reversing recent softening via clinician activation and panel conversions. Management highlights early 2026 NICU traction from new leadership and peer-to-peer sales, positioning it as the top expansion contributor at 7-8% of growth. Competition draws little concern; GeneDx touts sixfold sales force edge, two-week TATs, and INFINITY's accuracy moat. Reimbursement conservatism in new markets like peds and prenatal leaves upside. Investors will eye sales ramp productivity. Q1 tests the thesis.
Key Stats
Market Cap
4.10BP/E (TTM)
1288.36Basic EPS (TTM)
0.11Dividend Yield
0%Recent Filings
8-K
8-K
10-K
8-K
8-K
Q3 revenue beats, guidance up
IPO
Website
Employees
Sector
Industry
APDN
Applied DNA Sciences, Inc.
5.62+1.35
DGX
Quest Diagnostics Incorporated
178.66-5.45
GH
Guardant Health, Inc.
100.00-2.67
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
LDDD
LONGDUODUO CO LTD.
0.59+0.00
MEHCQ
CHROME HLDG CO
3.50+0.00
NEO
NeoGenomics, Inc.
11.67-0.25
PRE
Prenetics Global Limited
16.58+1.95
QGEN
Qiagen N.V.
45.01-0.43